

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 7446

**Title:** Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease

**Reviewer code:** 00740229

**Science editor:** Qi, Yuan

**Date sent for review:** 2013-11-20 20:41

**Date reviewed:** 2013-12-01 06:46

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

COMMENTS TO AUTHORS This is a comprehensive article that gathers information about the importance of studying of several SNPs in anti-TNF medication response in Greek patients with Crohn disease. This article is advisable for publication, although it shows some problems that will be described below. The number of patients is very low to draw strong conclusions. This point should be appointed in discussion. The title is not correct, the SNPs rs4411591 is not associated with IBD. It should be changed. i.e "Study of association of" You should add other recent articles respect to other SNPs implicated in anti-TNF response (i.e. Genetic polymorphisms of tumour necrosis factor alpha (TNF- $\alpha$ ) promoter gene and response to TNF- $\alpha$  inhibitors in Spanish patients with inflammatory bowel disease. Int J Immunogenet. 2013 Apr 17. doi: 10.1111/iji.12059. [Epub ahead of print]). Were all patients treated with IFX? Did none of them receive certolizumab or adalimumab?. Were the primers designed by the authors or previously published?. If the primers were previously published, the reference should be put. There is a typographical error in Table 1. Gastroenteric-Gastroenteric.

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 7446

**Title:** Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease

**Reviewer code:** 02529876

**Science editor:** Qi, Yuan

**Date sent for review:** 2013-11-20 20:41

**Date reviewed:** 2013-12-06 20:55

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

In the article entitled : " Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease" Diamantis Thomas and co-authors show the results of the investigation of the correlation between the rs1568885, rs1813443 and rs4411591 polymorphisms and response to infliximab in a cohort of Greek patients with Crohn's disease. The analysis was performed on data from 126 patients with newly diagnosed Crohn's disease based on standard clinical, endoscopic, radiological, and pathological criteria and treated with Infliximab. They assessed clinical and serological responses using the Harvey-Bradshaw Index and serum CRP levels respectively and evaluated the endoscopic response by ileocolonoscopy, which was performed at baseline and after 12-20 weeks of therapy. They evaluated for genotyping genomic DNA extracted from whole peripheral blood. There were 80 complete responder patients (63.49%) and 32 (25.39%) partial responders to infliximab, and 14 (11.11%) primary non responders. The TT genotype of the rs1568885 was significantly related to partial response ( $p=0.024$ ) and resistance to infliximab ( $p=0.007$ ) while the AT genotype was more frequent in partial responders ( $p=0.035$ ) and in primary non-responders ( $p=0.032$ ). As for the rs1813443, the CC genotype was found to be associated with partial response ( $p=0.005$ ) and primary resistance ( $p=0.002$ ) to infliximab while no association was found between the rs4411591 polymorphism and the clinical response to infliximab. They conclude that the rs1568885 and rs1813443 polymorphisms are associated with clinical and biochemical response to infliximab in Greek patients with Crohn's disease. The study is interesting, and the results and conclusion are of sufficient notice. The sample size is small, anyway the authors used Yates corrections accounting for low statistical power. MAJOR CONCERNS In



## Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

---

the abstract the word “newly” is misleading. Please specify if the patients are naïve to biological drugs or only to infliximab, and how many patients were treated with other biological drugs. In the results section confidence interval must be added. OR cannot be showed in this way, and also in the discussion section the large differences must be considered In table 2 must be added the percentages There are many typos that must be corrected.

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 7446

**Title:** Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease

**Reviewer code:** 02529555

**Science editor:** Qi, Yuan

**Date sent for review:** 2013-11-20 20:41

**Date reviewed:** 2013-12-08 06:21

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

The manuscript entitled 'Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease' by Diamantis Thomas and colleagues, aimed at correlating rs1568885, rs1813443 and rs4411591 polymorphisms with response to infliximab in a cohort of CD patients. The manuscript is well written and the rationale clearly developed throughout the text. Conciseness and interesting outwards in using IFX in autoimmune diseases are a strength of the paper.